News | March 06, 2023
Par Drugs and Chemicals receives WHO-GMP certificate
The audit was commenced for newly renovated manufacturing Block 1, Block 2, and Block 3
The audit was commenced for newly renovated manufacturing Block 1, Block 2, and Block 3
The company expects the GMP approval from Saudi Food and Drug Authority (SFDA) to soon pave the way for marketing authorizations from the largest market in the GCC region
The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.
The company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.
The company increases its efficiency and is able to face the growing demand for its services.
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
